Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure

What Was Tested

This randomized controlled trial paper looks at Teduglutide (GLP-2 analog).

However, the effects of teduglutide on parenteral support vary among patients.

The researchers performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response.

Who Took Part

The study group was 85 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The researchers collected data from 85 patients with SBS with intestinal failure, according to the European Society for Clinical Nutrition and Metabolism classification system, who received teduglutide or placebo between November 25, 2008, and January 4, 2011, at 27 sites in 10 countries.

Two-sided t tests were used for comparisons between treatment groups.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Teduglutide (GLP-2 analog) and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Teduglutide (GLP-2 analog) group a baseline to be compared against.

Correlation analyses were conducted using simple linear regression models, with unadjusted r2 values reported.

What Was Measured

Topics PubMed links to this paper include Gastrointestinal Agents, Intention to Treat Analysis, Intestines, Linear Models, Parenteral Nutrition, Peptides and Recovery of Function.

The authors tagged it with the keywords GLP-2 Receptor Agonist, IBD and Short-Gut Syndrome.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Teduglutide (GLP-2 analog) in 85 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Gastroenterology), a journal based in United States.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.